RegenXBio (RGNX) Stock Forecast & Price Target

Compare

945 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGNX Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

RegenXBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGNX Stock 12 Month Forecast

Average Price Target

$31.43

▲(245.76%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for RegenXBio in the last 3 months. The average price target is $31.43 with a high forecast of $50.00 and a low forecast of $21.00. The average price target represents a 245.76% change from the last price of $9.09.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","28":"$28","51":"$51","16.5":"$16.5","39.5":"$39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,16.5,28,39.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.23,11.443076923076923,14.656153846153845,17.869230769230768,21.082307692307694,24.295384615384616,27.50846153846154,30.72153846153846,33.934615384615384,37.14769230769231,40.360769230769236,43.57384615384615,46.786923076923074,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.23,10.014615384615386,11.79923076923077,13.583846153846153,15.368461538461538,17.153076923076924,18.93769230769231,20.72230769230769,22.506923076923076,24.29153846153846,26.076153846153847,27.86076923076923,29.645384615384614,{"y":31.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.23,9.212307692307693,10.194615384615386,11.176923076923078,12.15923076923077,13.141538461538463,14.123846153846154,15.106153846153846,16.088461538461537,17.07076923076923,18.053076923076922,19.035384615384615,20.017692307692307,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.07,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$31.43

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$8.5

Hold

-6.49%

Downside

Reiterated

07/23/25

RegenXBio's overall score reflects significant financial challenges and valuation concerns, partly offset by positive developments in its clinical pipeline and strategic partnerships. The recent royalty monetization deal adds financial stability, but regulatory uncertainties and competitive pressures remain key risks.

Judah FrommerMorgan Stanley

Morgan Stanley

$24

Buy

164.03%

Upside

Reiterated

07/17/25

RegenXBio: Strong Financials and Undervalued Growth Potential Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$25→$21

Buy

131.02%

Upside

Reiterated

07/07/25

RBC Capital Remains a Buy on RegenXBio (RGNX)

Alec StranahanBank of America Securities

Bank of America Securities

$22

Buy

142.02%

Upside

Reiterated

06/16/25

RegenXBio's Strategic Approach and Promising Outlook Earns Buy Rating

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/15/25

RegenXBio Positioned for Success Amidst SRPT's Elevidys Concerns: Analyst Recommends Buy

Paul ChoiGoldman Sachs

Goldman Sachs

―

Hold

―

Reiterated

06/06/25

Goldman Sachs Remains a Hold on RegenXBio (RGNX)

Yi ChenH.C. Wainwright

H.C. Wainwright

$34

Buy

274.04%

Upside

Reiterated

06/06/25

Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio's RGX-202

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$40

Buy

340.04%

Upside

Reiterated

06/05/25

Stifel Nicolaus Remains a Buy on RegenXBio (RGNX)

Sean McCutcheonRaymond James

Raymond James

$29

Buy

219.03%

Upside

Reiterated

06/05/25

Raymond James Sticks to Their Buy Rating for RegenXBio (RGNX)

Gena WangBarclays

Barclays

$50

Buy

450.06%

Upside

Reiterated

05/13/25

RegenXBio (RGNX) Receives a Buy from Barclays

William MaughanClear Street

Clear Street

$50

Buy

450.06%

Upside

Initiated

03/31/25

Clear Street starts Regenxbio Inc. (RGNX) at Buy, PT $50Clear Street analyst Bill Maughan initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Buy rating and a price target of $50.00.

Brian SkorneyRobert W. Baird

Robert W. Baird

$39

Buy

329.04%

Upside

Reiterated

03/19/25

Bairds Brian Skorney Comments on Regenxbio Inc. (RGNX): We also think its favorable that REGENXBIO is able to learn from Elevidys faultsBaird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX)

Daniil GataulinChardan Capital

Chardan Capital

$52

Buy

472.06%

Upside

Reiterated

11/19/24

We note that a 12-yo patient treated at DL2 did not have a matched natural history external control for NSAA, but also note that DMD patients aged 8+ yrs generally are in a rapid decline phase for NSAA, whereas the patient in the current study has a notable improvement in NSAA score. A doctor on the call noted the beneficial effects that the treatment has had on the patients' daily lives, highlighting one patient who was able to participate in a six-mile community bike ride.

Danielle BrillTruist Financial

Truist Financial

$18

Buy

98.02%

Upside

Reiterated

11/18/24

Raymond James reiterates Outperform Rating on Regenxbio Inc. (RGNX)Raymond James analyst Danielle Brill reiterated an Outperform rating and $18.00 price target on Regenxbio Inc. (NASDAQ: RGNX).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$8.5

Hold

-6.49%

Downside

Reiterated

07/23/25

Judah FrommerMorgan Stanley

Morgan Stanley

$24

Buy

164.03%

Upside

Reiterated

07/17/25

RegenXBio: Strong Financials and Undervalued Growth Potential Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$25→$21

Buy

131.02%

Upside

Reiterated

07/07/25

RBC Capital Remains a Buy on RegenXBio (RGNX)

Alec StranahanBank of America Securities

Bank of America Securities

$22

Buy

142.02%

Upside

Reiterated

06/16/25

RegenXBio's Strategic Approach and Promising Outlook Earns Buy Rating

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/15/25

RegenXBio Positioned for Success Amidst SRPT's Elevidys Concerns: Analyst Recommends Buy

Paul ChoiGoldman Sachs

Goldman Sachs

―

Hold

―

Reiterated

06/06/25

Goldman Sachs Remains a Hold on RegenXBio (RGNX)

Yi ChenH.C. Wainwright

H.C. Wainwright

$34

Buy

274.04%

Upside

Reiterated

06/06/25

Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio's RGX-202

Annabel SamimyStifel Nicolaus

Stifel Nicolaus

$40

Buy

340.04%

Upside

Reiterated

06/05/25

Stifel Nicolaus Remains a Buy on RegenXBio (RGNX)

Sean McCutcheonRaymond James

Raymond James

$29

Buy

219.03%

Upside

Reiterated

06/05/25

Raymond James Sticks to Their Buy Rating for RegenXBio (RGNX)

Gena WangBarclays

Barclays

$50

Buy

450.06%

Upside

Reiterated

05/13/25

RegenXBio (RGNX) Receives a Buy from Barclays

William MaughanClear Street

Clear Street

$50

Buy

450.06%

Upside

Initiated

03/31/25

Clear Street starts Regenxbio Inc. (RGNX) at Buy, PT $50Clear Street analyst Bill Maughan initiates coverage on Regenxbio Inc. (NASDAQ: RGNX) with a Buy rating and a price target of $50.00.

Brian SkorneyRobert W. Baird

Robert W. Baird

$39

Buy

329.04%

Upside

Reiterated

03/19/25

Daniil GataulinChardan Capital

Chardan Capital

$52

Buy

472.06%

Upside

Reiterated

11/19/24

Danielle BrillTruist Financial

Truist Financial

$18

Buy

98.02%

Upside

Reiterated

11/18/24

Raymond James reiterates Outperform Rating on Regenxbio Inc. (RGNX)Raymond James analyst Danielle Brill reiterated an Outperform rating and $18.00 price target on Regenxbio Inc. (NASDAQ: RGNX).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RegenXBio

1 Month

xxx

Success Rate

8/13 ratings generated profit

Average Return

+9.18%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +9.18% per trade.

3 Months

xxx

Success Rate

6/13 ratings generated profit

Average Return

-7.56%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -7.56% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

5/11 ratings generated profit

Average Return

-8.33%

reiterated a buy rating last month

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -8.33% per trade.

2 Years

xxx

Success Rate

5/11 ratings generated profit

Average Return

-10.91%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 45.45% of your transactions generating a profit, with an average return of -10.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGNX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGNX has received 21 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. RGNX average Analyst price target in the past 3 months is 31.43.

Each month's total comprises the sum of three months' worth of ratings.

RGNX Financial Forecast

RGNX Earnings Forecast

Next quarter’s earnings estimate for RGNX is -$0.94 with a range of -$1.34 to $1.06. The previous quarter’s EPS was $0.12. RGNX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year RGNX has Preformed in-line its overall industry.

RGNX Sales Forecast

Next quarter’s sales forecast for RGNX is $38.70M with a range of $19.20M to $142.89M. The previous quarter’s sales results were $89.01M. RGNX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year RGNX has Preformed in-line its overall industry.

RGNX Stock Forecast FAQ

What is RGNX’s average 12-month price target, according to analysts?

Based on analyst ratings, RegenXBio Inc.’s 12-month average price target is 31.43.

What is RGNX’s upside potential, based on the analysts’ average price target?

RegenXBio Inc. has 245.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RGNX a Buy, Sell or Hold?

RegenXBio Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is RegenXBio Inc.’s price target?

The average price target for RegenXBio Inc. is 31.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $21.00. The average price target represents 245.76% Increase from the current price of $9.09.

What do analysts say about RegenXBio Inc.?

RegenXBio Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RGNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

RegenXBio (RGNX) Stock Forecast & Price Target

RGNX Analyst Ratings

RGNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RegenXBio

RGNX Analyst Recommendation Trends

RGNX Financial Forecast

RGNX Earnings Forecast

RGNX Sales Forecast

RGNX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts